<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Targeted molecular radiotherapy opens unprecedented opportunities to eradicate <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells with minimal irradiation of <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
<SENT sid="1" pm="."><plain>Described in this study are radioactive cyclosaligenyl monophosphates designed to deliver lethal doses of radiation to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>These compounds can be radiolabeled with SPECT- and PET-compatible radionuclides as well as radionuclides suitable for Auger electron therapies </plain></SENT>
<SENT sid="3" pm="."><plain>This characteristic provides an avenue for the personalized and comprehensive treatment strategy that comprises diagnostic imaging to identify sites of disease, followed by the targeted molecular radiotherapy based on the imaging results </plain></SENT>
<SENT sid="4" pm="."><plain>The developed radiosynthetic methods produce no-carrier-added products with high radiochemical yield and purity </plain></SENT>
<SENT sid="5" pm="."><plain>The interaction of these compounds with their target, butyrylcholinesterase, depends on the stereochemistry around the P atom </plain></SENT>
<SENT sid="6" pm="."><plain>IC(50) values are in the nanomolar range </plain></SENT>
<SENT sid="7" pm="."><plain>In vitro studies indicate that radiation doses delivered to the cell nucleus are sufficient to kill cells of several difficult to treat <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> and ovarian and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
</text></document>